Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02828228
Other study ID # 01/2016/UCK
Secondary ID
Status Recruiting
Phase N/A
First received June 8, 2016
Last updated July 6, 2016
Start date February 2016
Est. completion date February 2019

Study information

Verified date July 2016
Source University Clinical Centre, Gdansk
Contact Magdalena Slominska-Fraczek, MD,
Phone 694844420
Email fraczek@gumed.edu.pl
Is FDA regulated No
Health authority Poland: Ethics Committee
Study type Interventional

Clinical Trial Summary

1. Analyze the influence of vitamin D supplementation in obese children during weight-loss program on BMI, body composition and bone mineral density.

2. Analyze the influence of vitamin D supplementation on the risk profile of obesity-related complications, namely impaired tolerance of glucose, insulin resistance, dyslipidemia and arterial hypertension, in obese children participating in weight-loss program.

3. Analyze the prevalence of vitamin D deficiency among obese children.

4. Analyze the risk factors of vitamin D deficiency in obese children (age, gender, pubertal status).


Description:

The study will be conducted as a continuation and development of "6-10-14 for Health" program. The first phase of the program, financed by the municipality of Gdansk, was conducted in 2011-2013. The program comprised of screening and survey conducted among all 6-, 10- and 14-year-old children attending primary and grammar schools. A total of 18 162 children (including 7 448 6-year olds, 6 720 10-year olds and 3 994 14-year olds) were examined. A group of children with risk factors of civilization-related diseases (overweight and obesity defined according to BMI percentile charts. was identified on the basis of the screening. This group included 2 798 (16.32%) children, among them 9.17% of 6-years of age, 19.30% of 10-years and 20.48% of 14-years). All these children were qualified to intervention and education program. A total of 1 627 children qualified on the basis of screening eventually took part in the first edition of the program.

A total of 4 meetings with participating children and their caregivers were scheduled during the 12-month-long education and intervention program: at enrollment, and 3, 6 and 12 months thereafter. The meetings had form of individual consultations with various specialists. The first visit included complex medical examination, discussion on a health status of a child, interpretation of laboratory findings, and consultations with dietician, psychologist and physical education specialist. After consulting all the specialists involved in the program, individual protocol of health intervention was developed for every child. The objectives of the intervention included modification of diet, increasing health activity level and strengthening of health-seeking behaviors of child's family members. Adherence to the protocol and achieved results were evaluated during follow-up meetings with the specialists, and constituted the basis for development of individualized intervention plans for subsequent months.

The preliminary evaluation of the program effects was conducted in the group of 300 participants. The average percentile of BMI at enrollment to the program and after 12 months of participation amounted to 92.96 and 88.83, respectively. Participation in the program was reflected by a significant decrease in BMI percentile (p=0.0001), as well as by a significant drop off in fat mass content measured by bioelectrical impedance, from 39.0% to 31.4% (p=0.0001).

On the basis of these findings, the municipality of Gdansk decided to support the program for 2014-2016.

The experiment will follow a pattern of double blind randomized study. The enrolled subjects will be randomly assigned to one of the two groups:

Group 1 - weight-loss program for 52 weeks + vitamin D 1200 (IU) daily for 26 weeks Group 2 - weight-loss program for 52 weeks +placebo daily for 26 weeks

Visit I: enrollment:

- medical history, physical examination

- interpretation of laboratory findings (the tests conducted during screening + concentration of vitamin D),

- anthropometric evaluation and analysis of body composition (bioimpedance method)

- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention

- Kasch Pulse Recovery Test

- determination of hs-C-reactive protein, Interleukin 6, chemerin and adiponectin concentrations in blood samples obtained during screening

- informing parents about the objectives and protocol of the study

- obtaining written informed consent for participation in the study

- randomization to GROUP I or II

- densitometry (DXA) - within one week after enrollment

Visit II: after 13 weeks:

- medical history, physical examination

- anthropometric evaluation and analysis of body composition (bioimpedance method)

- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention

Within a week prior to Visit III - obtaining blood (ca. 5 ml) for laboratory testing (complete blood count, lipid profile, hs-C-reactive protein, oral glucose tolerance test, insulin, Interleukin 6, adiponectin and chemerin concentrations

Visit III: after 26 weeks:

- medical history, physical examination

- interpretation of laboratory findings

- anthropometric evaluation and analysis of body composition (bioimpedance method)

- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention

- obtaining blood for laboratory testing

- termination of active compound/placebo administration

Visit IV: after 52 weeks:

- medical history, physical examination

- anthropometric evaluation and analysis of body composition (bioimpedance method)

- consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention

- densitometry (DXA) - within one week after terminating the study


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date February 2019
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender Both
Age group 6 Years to 14 Years
Eligibility Inclusion Criteria:

- overweight (BMI between the 85th and 95th percentile) or obesity (BMI > 95th percentile), identified on the basis of anthropometric parameters

- blood concentration of 25(OH)D3 < 30 ng/ml

- written consent of legal guardians

Exclusion Criteria:

- Chronic conditions (asthma or allergies, inflammatory diseases of connective tissue, gastrointestinal disorders, diseases of kidneys and liver, disorders of bone metabolism)

- Contraindications to administration of vitamin D

- Administration of any preparation containing vitamin D, calcium, or steroid hormones during 3 months preceding the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Vitamin D 1200 IU
Vitamin D 1200 IU once a day for 26 weeks
Placebo
placebo once a day for 26 weeks

Locations

Country Name City State
Poland IUCCGdansk Gdansk Pomorskie

Sponsors (2)

Lead Sponsor Collaborator
University Clinical Centre, Gdansk Nutricia Foundation

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bone mineral density Increase in bone mineral density during weight-loss program and vitamin D supplementation 12 months No
Secondary Blood level of vitamin D Changes in blood level of vitamin D after supplementation 12 months No
Secondary Arterial blood pressure Change in blood pressure afer weight-loss and vitamin D supplementation 12 months No
Secondary Lipid profile Change of lipid profile after weight-loss and vitamin D supplementation 12 months No
Secondary Oral Glucose Tolerance Test Change of biochemical parameters after weight-loss and vitamin D supplementation 12 months No
Secondary Chemerin Change in chemerin level 12 months No
Secondary BMI (kg/m2) Change of BMI during 12-months weight loss-program and supplementation of vitamin D 12 months No
Secondary Fat mass (kg) Change in fat free mass during 12-months weight-loss programme and supplementation of vitamin D 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2